EGFR and mycosis fungoides: In another phase 1 trial, miR-16 was used via delivery in “minicells” targeted to EGFR (called TargomiRs) in patients with advanced mesothelioma (NCT02369198) resistant to standard therapy, but the success of partial remission was overshadowed by side effects of severe cardiac toxicity, fever, and chills [386] Another trial with a miRNA-based approach used cobomarsen, an inhibitor of miR-155, in patients with mycosis fungoides (NCT02580552 clinicaltrials.gov).